Arcutis Biotherapeutics (ARQT) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free ARQT Stock Alerts $8.66 +0.07 (+0.81%) (As of 05/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 8:39 AM | insidertrades.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $15,992.75 in StockMay 29 at 10:29 PM | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Masaru Matsuda Sells 1,775 SharesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Masaru Matsuda sold 1,775 shares of Arcutis Biotherapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $9.01, for a total value of $15,992.75. Following the sale, the insider now directly owns 188,508 shares of the company's stock, valued at approximately $1,698,457.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.May 29 at 6:47 AM | marketbeat.comFranklin Resources Inc. Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Franklin Resources Inc. grew its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 260.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,655,544 shares of the coMay 28 at 2:08 AM | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $27.00 Consensus Target Price from AnalystsMay 25, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating onMay 24, 2024 | finance.yahoo.comAnalysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This WeekMay 23, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%May 23, 2024 | marketbeat.comGW&K Investment Management LLC Lowers Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)GW&K Investment Management LLC lessened its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 20.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,640,325 shares of the company's sMay 22, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading 3.7% Higher Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.7%May 21, 2024 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Larry Todd Edwards Sells 7,640 Shares of StockMay 21, 2024 | insidertrades.comLarry Todd Edwards Sells 7,640 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockMay 20, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Larry Todd Edwards Sells 7,640 SharesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) SVP Larry Todd Edwards sold 7,640 shares of the business's stock in a transaction on Friday, May 17th. The shares were sold at an average price of $8.98, for a total transaction of $68,607.20. Following the transaction, the senior vice president now directly owns 140,360 shares in the company, valued at $1,260,432.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.May 20, 2024 | seekingalpha.comArcutis Stock: Sales Expansion Momentum Puts It On A Good TrajectoryMay 16, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.8%Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.8%May 16, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Significant Increase in Short InterestArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 21,690,000 shares, a growth of 10.3% from the April 15th total of 19,660,000 shares. Based on an average daily volume of 3,810,000 shares, the short-interest ratio is currently 5.7 days.May 15, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Arcutis Biotherapeutics Amid Zoryve’s Robust Sales PerformanceMay 15, 2024 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comQ1 2024 Arcutis Biotherapeutics Inc Earnings CallMay 15, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Announces Earnings Results, Beats Estimates By $0.28 EPSArcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.28. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative return on equity of 294.85%. The company had revenue of $49.57 million during the quarter. During the same period in the prior year, the firm posted ($1.31) earnings per share.May 15, 2024 | marketbeat.comNeedham & Company LLC Raises Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00Needham & Company LLC raised their target price on Arcutis Biotherapeutics from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday.May 15, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up on Analyst UpgradeArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up Following Analyst UpgradeMay 15, 2024 | markets.businessinsider.comA Balanced Outlook: Maintaining Hold on Arcutis Amidst Zoryve’s Mixed Performance and Potential Growth CatalystsMay 15, 2024 | finance.yahoo.comArcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 14, 2024 | msn.comArcutis Biotherapeutics Stock Climbs After Blockbuster Q1 ResultsMay 14, 2024 | investorplace.comARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | markets.businessinsider.comArcutis Biotherapeutics: Strong Prescription Growth Fuels Buy RatingMay 14, 2024 | globenewswire.comArcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | msn.comArcutis Biotherapeutics Q1 2024 Earnings PreviewMay 13, 2024 | globenewswire.comExpert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyMay 11, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases Shares of 194,461 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Los Angeles Capital Management LLC purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 194,461 shMay 10, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%May 7, 2024 | marketbeat.comArcutis Biotherapeutics (ARQT) Set to Announce Earnings on TuesdayArcutis Biotherapeutics (NASDAQ:ARQT) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591309)May 4, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.7% Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 6.7%May 3, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9%May 1, 2024 | marketbeat.comabrdn plc Acquires New Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)abrdn plc bought a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 148,874 shares of the company's stock, valued atApril 30, 2024 | marketbeat.comFederated Hermes Inc. Buys 461,469 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Federated Hermes Inc. lifted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 769.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 521,469 shares of the company's stock aApril 29, 2024 | globenewswire.comArcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 26, 2024 | marketbeat.comArcutis Biotherapeutics Sees Unusually High Options Volume (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the target of unusually large options trading on Friday. Stock investors purchased 5,056 call options on the stock. This is an increase of 79% compared to the typical daily volume of 2,821 call options.April 26, 2024 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue ForecastsApril 25, 2024 | marketbeat.comJennison Associates LLC Purchases 4,633,907 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Jennison Associates LLC lifted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 104.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,066,082 shares of the company'April 22, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)April 18, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.2%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.2%April 16, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Invests $462,000 in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)DekaBank Deutsche Girozentrale bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 140,000 shares of the company's stock, valued at approximatelApril 13, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest UpdateArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 19,260,000 shares, a growth of 28.5% from the March 15th total of 14,990,000 shares. Based on an average daily trading volume, of 4,760,000 shares, the days-to-cover ratio is currently 4.0 days.April 12, 2024 | morningstar.comArcutis Biotherapeutics Inc Ordinary Shares ARQTApril 12, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.8%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.8%April 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)April 12, 2024 | markets.businessinsider.comEvaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address 🚀 Tap into this explosive trade opportunity asap (Ad)I learned about these explosive stocks during my two decades on Wall Street… And used them to help grow my old hedge fund from just a few million to over $700 million dollars*. So it’s safe to say… these bad boys work. What’s the secret behind these special trades? Well, right now, I’m going public with the unique strategy behind these “Calendar Stocks”… Go here to see how you can exploit my next “Calendar Stock”. ARQT Media Mentions By Week ARQT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.980.81▲Average Medical News Sentiment ARQT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼94▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INVA News Today OCUL News Today KNSA News Today PHAT News Today SUPN News Today ORIC News Today NKTX News Today KPTI News Today BTAI News Today ALKS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeThis unknown company solves the biggest issue with AIManward PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.